May 15 (Reuters) - Genfit SA GNFT.PA :
* REPORTED ON TUESDAY FIRST QUARTER 2024 FINANCIAL
INFORMATION
* REVENUES FOR FIRST THREE MONTHS OF 2024 AMOUNTED TO EUR
1.1
MILLION COMPARED TO EUR 5.0 MILLION FOR SAME PERIOD IN 2023
* AS OF MARCH 31, 2024, CO’S CASH AND CASH EQUIVALENTS
AMOUNTED TO
EUR 74.0 MLN VERSUS EUR 128.6 MLN AS OF MARCH 31, 2023
* EXPECTS ITS EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE
IT TO
FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS
UNTIL ABOUT Q4 2025
* THIS ESTIMATION INCLUDES EXPECTATIONS TO RECEIVE FUTURE
MILESTONE REVENUE IN 2024, SUBJECT TO APPROVAL BY APPLICABLE
REGULATORY AUTHORITIES AND US AND EUROPEAN COMMERCIAL LAUNCHES
OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS (PBC) BY IPSEN
IPN.PA , REPRESENTING ABOUT EUR 75.2 MLN
Source text for Eikon: ID:nGNE631xp9
Further company coverage: GNFT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))